The effects of group occupational therapy on cognition and psychosocial functioning in adults with schizophrenia

Effects of a structured group occupational therapy programme plus treatment as usual compared with treatment as usual alone on cognition, psychopathology, functioning, quality of life and satisfaction with health services in adults with schizophrenia: a randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN43725423

Enrollment

Registered

2026-07-10

Start date

2025-09-01

Completion date

Unknown

Last updated

2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia in adults receiving public mental health services Mental and Behavioural Disorders

Interventions

Participants are randomly allocated to either an intervention group or a control group using a computer-generated randomisation sequence with allocation concealment through sealed opaque envelopes. Th

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Adults aged 18–70 years with a diagnosis of schizophrenia (ICD-10 F20) 2. Clinically stable for at least six months 3. Receiving follow-up care from the Psychiatric Department of the General Hospital of Argolida for at least one year 4. Able to provide informed consent and participate in group occupational therapy

Exclusion criteria

Exclusion criteria: 1. Neurological or developmental disorders 2. Intellectual disability or severe cognitive impairment unrelated to schizophrenia 3. Severe traumatic brain injury, current alcohol or substance abuse/dependence 4. Acute psychotic episode or severe relapse at enrolment 5. Inability to provide informed consent 6. Participation in another structured psychosocial intervention during the study

Design outcomes

Primary

Measure	Time frame
Global cognitive functioning measured using Addenbrooke's Cognitive Examination III (ACE-III) at Baseline (T0) and 3 months (T1);Global cognitive functioning measured using Mini-Mental State Examination (MMSE) at Baseline (T0) and 3 months (T1);Executive function and processing speed measured using Trail Making Test (TMT Parts A and B) at Baseline (T0) and 3 months (T1);Visuospatial and executive functioning measured using Clock Drawing Test (CDT) at Baseline (T0) and 3 months (T1)	—

Measure

Time frame

Global cognitive functioning measured using Addenbrooke's Cognitive Examination III (ACE-III) at Baseline (T0) and 3 months (T1);Global cognitive functioning measured using Mini-Mental State Examination (MMSE) at Baseline (T0) and 3 months (T1);Executive function and processing speed measured using Trail Making Test (TMT Parts A and B) at Baseline (T0) and 3 months (T1);Visuospatial and executive functioning measured using Clock Drawing Test (CDT) at Baseline (T0) and 3 months (T1)

—

Secondary

Measure	Time frame
Psychopathology measured using PANSS at Baseline (T0) and 3 months (T1);Health-related quality of life measured using SF-36 at Baseline (T0) and 3 months (T1);Satisfaction with health services measured using VSQ-9 at Baseline (T0) and 3 months (T1);Psychosocial functioning measured using Global Assessment of Functioning (GAF) at Baseline (T0) and 3 months (T1)	—

Countries

Greece

Contacts

Public ContactElpida Stratou

estratou@uniwa.gr+30 2751360356

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Jul 23, 2026